Skip to content
Catalyst

huperzine AFinding

Huperzine A has no detected effect on Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) score

no difference foundVery limited evidenceFinding

01 · The sentence it was drawn from

“Huperzine A 200 μg BID did not influence change in ADAS-Cog at 16 weeks.”
Quoted verbatim from A phase II trial of huperzine A in mild to moderate Alzheimer disease.
This finding among the 2 findings on its endpoint

huperzine A

Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) score

no difference found

Who
Adults with mild to moderate Alzheimer disease; multicenter trial, huperzine A 200 μg BID against placebo
Dose studied
huperzine A 200 μg BID, oral

Very limited evidencePMID 21502597 · 2011

02 · The study

Study
RCT
Duration
4 months

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

03 · The paper

Neurology
What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M6ZFQ93E0V5Z674SDZAS1FNE